CNR2 and amyotrophic lateral sclerosis: In ALS mouse models SOD1-G93A [301] and TDP-43-A315T [302], administration of a CB2 agonist (AM1241 0.3 or 3 mg/kg/day i.p. [301], or HU308 5 mg/kg/day i.p. [302]) from symptom onset prolonged survival in the AM1241 study and improved motor function and contributed to the preservation of motor neurons in the HU308 study.